Study of AZD3152 intramuscular injection or intravenous infusion in Healthy Japanese Adult Participants

Study identifier:D7000C00007

ClinicalTrials.gov identifier:NCT05932641

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3152 in Healthy Japanese Adults

Medical condition

COVID-19, SARS-CoV-2

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual Enrollment

24

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 31 Jul 2023
Estimated Primary Completion Date: 19 Dec 2024
Estimated Study Completion Date: 19 Dec 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria